论文部分内容阅读
目的研究重组人血管内皮抑制素(恩度)联合达卡巴嗪一线治疗晚期黑色素瘤的临床疗效以及对患者生存期的影响。方法选择2013年5月至2015年5月我院肿瘤科收治的经病理组织检查确诊的52例晚期黑色素瘤患者进行研究,随机均分为实验组和对照组。对照组患者采用达卡巴嗪治疗,实验组给予恩度联合达卡巴嗪治疗。采用实体瘤评价标准评定疗效,比较两组患者的客观有效率(ORR)、疾病控制率(DCR)以及无进展生存期(PFS)和总生存期(OS)。结果实验组和对照组患者ORR分别为34.62%、15.38%,两组比较差异无统计学意义(P>0.05);实验组和对照组DCR分别为76.92%、50.00%,实验组高于对照组,差异有统计学意义(P<0.05)。实验组PFS、OS高于对照组患者,但差异无统计学意义(P>0.05)。实验组和对照组不良反应发生率分别为34.62%、65.38%,实验组显著低于对照组,差异具有统计学意义(P<0.05)。结论恩度联合达卡巴嗪一线治疗可在短期内有效缓解、控制晚期黑色素瘤病情,延长患者PFS和OS。
Objective To study the clinical efficacy of recombinant human endostatin (Endostar) combined with dacarbazine in the treatment of advanced melanoma and its effect on the survival of patients. Methods From May 2013 to May 2015, 52 patients with advanced melanoma diagnosed by pathological examination in our department of oncology were randomly divided into experimental group and control group. Patients in the control group were treated with dacarbazine, and those in the experimental group were given Endo combined with dacarbazine. The curative effect was evaluated by solid tumor evaluation criteria. The objective effective rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were compared between the two groups. Results The ORR of experimental group and control group were 34.62% and 15.38%, respectively. There was no significant difference between the two groups (P> 0.05). The DCR of experimental group and control group were 76.92% and 50.00% , The difference was statistically significant (P <0.05). The PFS and OS of the experimental group were higher than those of the control group, but the difference was not statistically significant (P> 0.05). The incidences of adverse reactions in experimental group and control group were 34.62% and 65.38% respectively, which were significantly lower in experimental group than those in control group (P <0.05). Conclusions Endo combined with dacarbazine first-line treatment can effectively relieve short-term, control the disease of advanced melanoma and prolong the PFS and OS of patients.